摘要
目的:对阿托伐他汀、瑞舒伐他汀、匹伐他汀、氟伐他汀、辛伐他汀、普伐他汀、洛伐他汀进行“有效性”“安全性”“药学特性”“经济性”“其他属性”5个维度的临床综合评价,以期为医疗机构药品遴选及科学、合理、安全用药提供参考。方法:应用《河北省三级公立医疗机构用药(化学药品)目录遴选评价表》(试行)评价方法,评价体系包含5个一级指标、18个二级指标、74个三级指标,对7种他汀进行临床综合评价。结果:评价的7个品种20个品规他汀类药物,阿托伐他汀77.9~82.1分、瑞舒伐他汀77.8~80.8分、辛伐他汀78~78.1分、匹伐他汀71.1~76.5分、氟伐他汀74~74.6分、洛伐他汀67.7~68.3分、普伐他汀65.7~69.1分。结论:他汀类药物是治疗血脂异常的首选药物,在临床治疗中有不同的优势。通过评价表对药品进行量化评分可为医疗机构药品遴选与科学、合理、安全用药提供直观的证据。
OBJECTIVE To perform a comprehensive clinical evaluation of atorvastatin,rosuvastatin,pivastatin,fluvastatin,simvastatin,pravastatin and lovastatin in five dimensions,including effectiveness,safety,pharmaceutical characteristics,economy and other attributes,so as to provide reference for drug selection and scientific,rational and safe drug use in medical institutions.METHODS Selection and Evaluation Form of Drug Use(Chemical Drugs)List in the Tertiary Public Medical Institutions in Hebei Province was used for the evaluation.The evaluation system included 5 level 1 indicators,18 level 2 indicators and 74 level 3 indicators,which were used for the clinical comprehensive evaluation of 7 statins.RESULTS Totally seven varieties and twenty product specifications were evaluated.The scores were as follows:atorvastatin 77.9-82.1,rosuvastatin 77.8-80.8,simvastatin 78-78.1,pivastatin 71.1-76.5,fluvastatin 74-74.6,lovastatin 67.7-68.3 and pravastatin 65.7-69.1.CONCLUSION Statins are the first choice for the treatment of dyslipidemia,but different statins have various advantages in clinical treatment.The quantitative scoring of drugs can provide intuitive evidence for drug selection and scientific,rational and safe drug use in medical institutions.
作者
董占军
薛朝军
邱学佳
田冬冬
任炳楠
朱晓冉
曹格溪
李宵
DONG Zhanjun;XUE Chaojun;QIU Xuejia;TIAN Dongdong;REN Bingnan;ZHU Xiaoran;CAO Gexi;LI Xiao(Department of Pharmacy,Hebei General Hospital,Hebei Shijiazhuang 050051,China)
出处
《中国医院药学杂志》
CAS
北大核心
2023年第19期2179-2186,共8页
Chinese Journal of Hospital Pharmacy
基金
河北省药学会他汀类药品临床综合评价专项课题(编号:Hbsyxh-DXKT-1)。
关键词
他汀类药物
血脂异常
药物临床综合评价
医疗机构
statins
dyslipidemia
comprehensive clinical evaluation of drugs
medical institution
